Lapatinib Recruiting Phase 2 Trials for Breast Diseases / Her2-Positive Breast Cancer / Capecitabine / HER2 Positive Breast Carcinoma / Neoplasms, Breast Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03273595Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer
NCT03500380A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer